Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Fineline Cube May 15, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company

Allergan Aesthetics Opens Shanghai Innovation Center for Medical Aesthetics

Fineline Cube Sep 29, 2022

Allergan Aesthetics, a division of AbbVie, has officially opened its Shanghai innovation center, marking a...

Company

Biosyngen to Establish Cell Therapy GMP Facility in Singapore

Fineline Cube Sep 29, 2022

Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...

Company

Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges

Fineline Cube Sep 29, 2022

China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85...

Company Medical Device

Parexel Opens Clinical Study Supply Chain Center in Suzhou

Fineline Cube Sep 29, 2022

US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply...

Company Drug

Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043

Fineline Cube Sep 29, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has...

Company Drug

Arctic Vision Enrolls First Patient in Phase III Study for ARVN002

Fineline Cube Sep 29, 2022

China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a...

Company Deals

3D Medicines Partners with Denfo Medical for Cancer Therapy Development

Fineline Cube Sep 29, 2022

China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group,...

Company Deals

Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278

Fineline Cube Sep 29, 2022

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with...

Company Deals

Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion

Fineline Cube Sep 29, 2022

Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured...

Company

Santen Pharmaceutical Launches New Plant Construction in Suzhou

Fineline Cube Sep 28, 2022

Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu...

Company Drug

Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma

Fineline Cube Sep 28, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and...

Company Deals

Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development

Fineline Cube Sep 28, 2022

Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with...

Company Deals

Merck Sharp & Dohme Partners with Sinopharm for Molnupiravir in China

Fineline Cube Sep 28, 2022

US-based Merck Sharp & Dohme (MSD, NYSE: MRK) has entered into a cooperation framework agreement...

Company Drug

NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 28, 2022

The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for...

Company

SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results

Fineline Cube Sep 28, 2022

SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private...

Company Drug

Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China

Fineline Cube Sep 28, 2022

China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...

Company Medical Device

MicroPort CardioFlow’s Alwide Plus Balloon Catheter Approved in Colombia

Fineline Cube Sep 28, 2022

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Deals

Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization

Fineline Cube Sep 28, 2022

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based...

Company Drug

Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China

Fineline Cube Sep 28, 2022

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...

Company Drug

Fosun Pharma Launches 20ml SPSB Liquid Product in US Market

Fineline Cube Sep 28, 2022

Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch...

Posts pagination

1 … 620 621 622 … 666

Recent updates

  • Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
  • Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”

Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.